Mark E. Cooper

5.9k total citations · 2 hit papers
67 papers, 4.6k citations indexed

About

Mark E. Cooper is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Molecular Biology. According to data from OpenAlex, Mark E. Cooper has authored 67 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Nephrology and 14 papers in Molecular Biology. Recurrent topics in Mark E. Cooper's work include Chronic Kidney Disease and Diabetes (20 papers), Diabetes Treatment and Management (11 papers) and Renin-Angiotensin System Studies (8 papers). Mark E. Cooper is often cited by papers focused on Chronic Kidney Disease and Diabetes (20 papers), Diabetes Treatment and Management (11 papers) and Renin-Angiotensin System Studies (8 papers). Mark E. Cooper collaborates with scholars based in Australia, United States and United Kingdom. Mark E. Cooper's co-authors include Richard E. Gilbert, Assam El‐Osta, Terri J. Allen, David Casley, Zemin Cao, Annabelle M Warren, Karin Jandeleit‐Dahm, Dimitria Vranes, George Jerums and Søren Tang Knudsen and has published in prestigious journals such as New England Journal of Medicine, Advanced Materials and Nature Communications.

In The Last Decade

Mark E. Cooper

66 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New-Onset Diabetes in Covid-19

2020 541 citations Mark E. Cooper, Zhonglin Chai et al. profile →
The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?

1999 541 citations Richard E. Gilbert, Mark E. Cooper Kidney International profile →

Peers

Countries citing papers authored by Mark E. Cooper

Since Specialization

Citations

This map shows the geographic impact of Mark E. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Cooper more than expected).

Fields of papers citing papers by Mark E. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Cooper. The network helps show where Mark E. Cooper may publish in the future.

Co-authorship network of co-authors of Mark E. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Cooper. A scholar is included among the top collaborators of Mark E. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Cooper. Mark E. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Altered oxidant and antioxidant levels are associated with vascular stiffness and diabetic kidney disease in type 1 diabetes after exposure to acute and chronic hyperglycemia 2024 ·Cardiovascular Diabetology ·(unknown), Elyse Di Marco, (unknown), (unknown), Luciano Bernardi, Mark E. Cooper, (unknown), (unknown)	3
2	The GLP-1 receptor agonist revolution comes to nephrology 2024 ·Nature Reviews Nephrology ·Merlin C. Thomas, Mark E. Cooper	1
3	The prognostic impact of the Stress Hyperglycemia Ratio on End‐Stage Renal Disease among patients with Diabetic Kidney Disease 2024 ·Diabetes Obesity and Metabolism ·Yutong Zou, Qing Yang, (unknown), Ke Liu, (unknown), (unknown), Zhonglin Chai, Mark E. Cooper, Fang Liu	3
4	A Fully Decentralized Randomized Controlled Study of As-Needed Albuterol–Budesonide Fixed-Dose Inhaler in Mild Asthma: The BATURA Study Design 2024 ·Journal of Asthma and Allergy ·Craig LaForce, Frank C. Albers, Mark E. Cooper, (unknown), (unknown), Robert C. Rees, (unknown)	3
5	An Engineered Nanosugar Enables Rapid and Sustained Glucose‐Responsive Insulin Delivery in Diabetic Mice 2023 ·Advanced Materials ·Rong Xu, Sukhvir Kaur Bhangu, Karly C. Sourris, (unknown), Marc‐Antoine Sani, John A. Karas, Karen Alt, Be׳eri Niego, (unknown), Quinn A. Besford, Brendan Dyett, (unknown), (unknown), Jonathan E. Shaw, Frank Caruso, Mark E. Cooper, Christoph E. Hagemeyer, Francesca Cavalieri	22
6	Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function 2021 ·Nature Reviews Nephrology ·Eoin Brennan, Phillip Kantharidis, Mark E. Cooper, Catherine Godson	160
7	Potential cardiorenal benefits of efpeglenatide in diabetes 2021 ·Nature Reviews Nephrology ·(unknown), Mark E. Cooper	4
8	A promising outlook for diabetic kidney disease 2018 ·Nature Reviews Nephrology ·Mark E. Cooper, Annabelle M Warren	21
9	Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets 2018 ·Nature Communications ·Lining Arnold Ju, James D. McFadyen, (unknown), Imala Alwis, Yunfeng Chen, (unknown), (unknown), (unknown), Anna C. Calkin, Eric I. Felner, Neale Cohen, Yuping Yuan, Simone M. Schoenwaelder, Mark E. Cooper, Cheng Zhu, Shaun P. Jackson	48
10	The relationship between heat shock protein 72 expression in skeletal muscle and insulin sensitivity is dependent on adiposity 2010 ·Metabolism ·Darren C. Henstridge, Josephine M. Forbes, Sally A. Penfold, Melissa F. Formosa, Sonia Dougherty, Anna Gasser, Maximilian de Courten, Mark E. Cooper, Bronwyn A. Kingwell, Barbora de Courten	18
11	Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia 2008 ·The Journal of Experimental Medicine ·Assam El‐Osta, Daniella Brasacchio, Dachun Yao, Alessandro Pocai, Peter L. Jones, Robert G. Roeder, Mark E. Cooper, Michael Brownlee	36
12	The Role of AGEs in Cardiovascular Disease 2008 ·Current Pharmaceutical Design ·Karin Jandeleit‐Dahm, Mark E. Cooper	92
13	Reduced tubular cation transport in diabetes: Prevented by ACE inhibition 2003 ·Kidney International ·Merlin C. Thomas, Chris Tikellis, Wendy C. Burns, Vicki Thallas, Josephine M. Forbes, Zemin Cao, Tanya M. Osicka, Leileata M. Russo, George Jerums, Hany Ghabrial, Mark E. Cooper, Phillip Kantharidis	47
14	Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion 2001 ·Journal of Hypertension ·Fabrice Bonnet, Mark E. Cooper, Robert M. Carey, David Casley, Zemin Cao	54
15	Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats 2001 ·Kidney International ·Zemin Cao, Louise M. Burrell, Ilkka Tikkanen, Fabrice Bonnet, Mark E. Cooper, Richard E. Gilbert	77
16	Allelic frequencies of host genetic variants influencing susceptibility to HIV-1 infection and disease in South African populations 2000 ·AIDS ·Carolyn Williamson, Shayne Loubser, (unknown), G Joubert, Teresa Smit, (unknown), (unknown), Mark E. Cooper, Elna van der Ryst	35
17	The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? breakdown → 1999 ·Kidney International ·Richard E. Gilbert, Mark E. Cooper	541
18	Renal expression of transforming growth factor-β inducible gene-h3 (βig-h3) in normal and diabetic rats 1998 ·Kidney International ·Richard E. Gilbert, Jennifer L. Wilkinson‐Berka, David W. Johnson, Alison J. Cox, Tina Soulis, Leonard L. Wu, Darren J. Kelly, G. Jerums, Carol A. Pollock, Mark E. Cooper	78
19	Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action 1998 ·Journal of Hypertension ·Zemin Cao, U. Lennart Hulthén, Terri J. Allen, Mark E. Cooper	18
20	Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes 1997 ·Diabetes ·Terri J. Allen, (unknown), David Casley, George Jerums, Mark E. Cooper	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact